Teva Pharma (TEVA) Reports In-Line Q1 EPS; Narrows Guidance

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.55, in-line with the analyst estimate of $0.55. Revenue for the quarter came in at $3.7 billion versus the consensus estimate of $3.74 billion.

GUIDANCE:

Teva Pharma sees FY2022 EPS of $2.40-$2.60, versus the consensus of $2.51. Teva Pharma sees FY2022 revenue of $15.4-1$6 billion, versus $15.6-$16.2 billion prior and the consensus of $15.97 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
• Vail Resorts taps bankers for potential activist defense, Semafor reports
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance